VIMTA LABS LTD.-$

Vimta Labs Ltd. announced its 36th Annual General Meeting (AGM) scheduled for Thursday, June 25, 2026, at 10:00 AM IST. The meeting will be held via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The notice and annual report for FY 2025-26 are available on the company's website. Agenda includes adopting financial statements, declaring a dividend of ₹2 per share, and director reappointment. Special business includes ratification of cost auditor remuneration and reappointment of Dr. S P Vasireddi as Executive Chairman.

Vimta Labs Ltd. has re-appointed Dr. S. P. Vasireddi (DIN 00242288) as Executive Chairman, based on the recommendations of the Nomination and Remuneration Committee and the approval of the Audit Committee. The re-appointment, approved by the Board of Directors on May 6, 2026, is subject to shareholder approval at the upcoming Annual General Meeting. His term will be for five years, from July 1, 2026, to June 30, 2031. Dr. Vasireddi's profile and experience are detailed in Annexure I, as per SEBI circulars dated July 13, 2023, and November 11, 2024.

Vimta Labs Ltd has announced that its Board of Directors, in a meeting held on May 6, 2026, recommended a dividend of ₹2 per share on equity shares with a face value of ₹2 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the upcoming Annual General Meeting. The record date for the dividend payment, pending shareholder approval, is set for June 18, 2026, and the payment will be made on or before July 8, 2026.

Vimta Labs Ltd announced its Q4 and FY26 financial results. FY26 revenue reached ₹4,163 Mn, a 19.5% increase YoY. EBITDA margins stood at 35.8%, and PAT margin at 18.6%. Q4 FY26 revenue was ₹1,120 Mn, up 11.5% YoY. The company highlighted strong performance in its Pharma and Food divisions, driven by sustained demand and customer confidence. Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, with the transfer completed on October 11, 2024.

Vimta Labs Ltd. announced its audited financial results for the year ended March 31, 2026. The Board of Directors recommended a dividend of ₹2 per share, subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for June 25, 2026. The board also approved the incorporation of a wholly-owned subsidiary in the USA and the reappointment of Dr. S. P. Vasireddi as Executive Chairman for five years, pending shareholder approval. The meeting commenced at 11:30 AM and concluded at 03:32 PM.

Vimta Labs Ltd. announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors recommended a dividend of ₹2 per share, subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for June 25, 2026. The board also approved the incorporation of a wholly-owned subsidiary in the USA and the reappointment of Dr. S. P. Vasireddi as Executive Chairman for five years, pending shareholder approval.

Vimta Labs Ltd has announced that its Board of Directors will convene a meeting on Wednesday, May 6, 2026. The primary agenda includes considering and approving the audited financial results for the fourth quarter and the full financial year ended March 31, 2026. Additionally, the board will discuss and potentially recommend the payment of a dividend on equity shares for the financial year ended March 31, 2026. In compliance with SEBI regulations, the trading window for insiders commenced its closure period from April 1, 2026, and will remain closed until 48 hours after the financial results are announced to the stock exchanges.

Vimta Labs Ltd. has announced the closure of its trading window for the fourth quarter and year ending 31st March 2026. The intimation was made by SUJANI VASIREDDI on 31st March 2026 at 15:09:49 +05'30'.

Vimta Labs Limited, a leading Contract Research and Testing Organisation, has announced its financial results for the quarter and nine months ended December 31, 2025. The company reported a total income of Rs. 1,005 Mn in Q3 FY26, reflecting a YoY growth of 10.2%. The EBITDA margins stood at 34.3% and the PAT margin was at 17.5%. The company's strategic direction remains confident and it will continue to invest in capabilities that enhance long-term value for clients, stakeholders, and the broader people wellness ecosystem.

Vimta Labs Ltd. has announced its unaudited financial results for the 3rd quarter and nine months ended on 31st December 2025. The company's revenue from operations has increased by 10.14% compared to the same period last year, reaching INR 3,439.82 million. The profit before exceptional items and tax stands at INR 890.00 million, a 24.99% increase compared to the same period last year. The board of directors has reviewed and approved these financial results in their meeting held on 28th January 2026.